Abstract 969P
Background
Alpha-fetoprotein (AFP) is widely used for HCC screening in at-risk populations, but its performance is suboptimal. Routine blood test panels provide insights on multiple cancer-related conditions and have shown to improve detection in other cancers. Hence, we explore the foundation for a new high-dimensional data approach taking multiple routine laboratory parameters and their intricate interactions into consideration with AI. In this study, a routine blood test signature for HCC derived from big clinical data is described
Methods
This is a population-based retrospective study. Patient records from 2000 to 2018 were retrieved from the Hong Kong Hospital Authority Data Collaboration Laboratory. CLD patients with and without HCC were identified based on ICD codes, antiviral drug history, virology test and radiology reports. Patients with decompensated CLD were excluded. Routine blood tests retrieved included CBC, LFT, RFT and clotting profile. Blood records within one month before the diagnosis of HCC and CLD patients were retrieved. Statistical analysis included descriptive statistics and Mann-Whitney U (MWU) test.
Results
The cohort yielded 223,862 patients including 31,149 patients with HCC (13.9%) and 192,713 without. Statistical test results showed a distinctive spectral signature for HCC patients compared to those without HCC. It is characterized by the concurrent presence of more significant liver function derangement (raised ALT, ALP, bilirubin, AST and decreased albumin), tendency for systemic inflammation (lower lymphocyte and RDW), tendency for bleeding (prolonged PT and APTT, low platelet) and suggestions of cachexia (lower albumin, creatinine and urea), all were statistically significant (P<0.05, MWU test)
Conclusions
This is the first study to describe a routine blood signature for HCC detection established by big clinical data. The spectral characteristics of HCC separated well from CLD controls. The novel spectrum provides solid clinical ground for the use of advanced machine learning to generate an interactive classification model to detect HCC. In a companion abstract, we describe the development of the proposed signature, which is shown to be superior to AFP in HCC screening.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Hong Kong University of Science and Technology.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
832P - Characterisation of EXS73565: A potent and selective MALT1 inhibitor with low drug-drug interaction risk and potential in lymphoma
Presenter: Major Gooyit
Session: Poster session 18
833P - New targets for adult T cell leukemia/lymphoma (ATLL): A map for ATLL immunotherapy
Presenter: Zahra Rezaei Borojerdi
Session: Poster session 18
834P - Phase II clinical study of VR-CAP regimen for first-line treatment of marginal zone lymphoma
Presenter: Junfeng Chu
Session: Poster session 18
835P - A safe and effective immunochemotherapy with oral sobuzoxane and etoposide for untreated diffuse large B cell lymphoma patients aged 80 and over
Presenter: Kaname Miyashita
Session: Poster session 18
838P - Matching-adjusted indirect comparison (MAIC) of axicabtagene ciloleucel (axi-cel) and epcoritamab (epcor) in relapsed/refractory (R/R) large B cell lymphoma (LBCL) after at least two prior systemic therapies (3L+)
Presenter: Olalekan Oluwole
Session: Poster session 18
840P - Genomic landscape, immune characteristics and prognostic mutation signature of extranodal NK/T cell lymphoma, nasal type in China
Presenter: Yue Chai
Session: Poster session 18
841P - Ki67-revised risk index to risk-stratify patients with extra-nodal natural killer/T cell lymphoma
Presenter: Shuo Li
Session: Poster session 18